Abstract
Pulmonary tuberculosis (TB) has again become a global problem: it infects 2.2 billion people world-wide, caused the deaths of over 3 million last year and will produce over 8 million new cases of TB this coming year. Although effective therapy is widely available for antibiotic susceptible strains of Mycobacterium tuberculosis, current drugs are relatively useless against multi-drug resistant infections (MDRTB). Mortality is almost complete within two years regardless of therapy, and in the case of co-infection with HIV/AIDS, mortality is 100% within a few months of diagnosis especially the M. tuberculosis strain in XDRTB. As of the time of this writing no new effective anti-TB drugs have been made available by the pharmaceutical industry and XDRTB. Because TB is an intracellular infection of the non-killing macrophage of the lung, any agent that is to prove effective must have activity against MDRTB and XDRTB strains that have been phagocytosed by the human macrophage. This review intents to provide cogent in vitro, ex vivo and in vivo evidence that supports the use of a variety of commonly available phenothiazines for the therapy of MDRTB and XDRTB, especially when the prognosis of the infection is poor and the use of the recommend agents can take place along lines of “compassionate therapy”. In addition, we will describe the macrophage assay as indispensable when an agent is to be further studied for its effectiveness as an anti-TB drug. In vitro studies if not complemented by ex vivo studies will for the most part be dead-ended since few agents that have activity in vitro have any activity against phagocytosed M. tuberculosis.
Keywords: Thioridazine, inhibitors of efflux pumps, macrophages, enhanced killing, multi-drug resistant tuberculosis, intracellular infections, K+ transport, phagolysosome
Infectious Disorders - Drug Targets
Title: Phenothiazines as Anti-Multi-Drug Resistant Tubercular Agents
Volume: 7 Issue: 3
Author(s): L. Amaral, M. Martins and M. Viveiros
Affiliation:
Keywords: Thioridazine, inhibitors of efflux pumps, macrophages, enhanced killing, multi-drug resistant tuberculosis, intracellular infections, K+ transport, phagolysosome
Abstract: Pulmonary tuberculosis (TB) has again become a global problem: it infects 2.2 billion people world-wide, caused the deaths of over 3 million last year and will produce over 8 million new cases of TB this coming year. Although effective therapy is widely available for antibiotic susceptible strains of Mycobacterium tuberculosis, current drugs are relatively useless against multi-drug resistant infections (MDRTB). Mortality is almost complete within two years regardless of therapy, and in the case of co-infection with HIV/AIDS, mortality is 100% within a few months of diagnosis especially the M. tuberculosis strain in XDRTB. As of the time of this writing no new effective anti-TB drugs have been made available by the pharmaceutical industry and XDRTB. Because TB is an intracellular infection of the non-killing macrophage of the lung, any agent that is to prove effective must have activity against MDRTB and XDRTB strains that have been phagocytosed by the human macrophage. This review intents to provide cogent in vitro, ex vivo and in vivo evidence that supports the use of a variety of commonly available phenothiazines for the therapy of MDRTB and XDRTB, especially when the prognosis of the infection is poor and the use of the recommend agents can take place along lines of “compassionate therapy”. In addition, we will describe the macrophage assay as indispensable when an agent is to be further studied for its effectiveness as an anti-TB drug. In vitro studies if not complemented by ex vivo studies will for the most part be dead-ended since few agents that have activity in vitro have any activity against phagocytosed M. tuberculosis.
Export Options
About this article
Cite this article as:
Amaral L., Martins M. and Viveiros M., Phenothiazines as Anti-Multi-Drug Resistant Tubercular Agents, Infectious Disorders - Drug Targets 2007; 7 (3) . https://dx.doi.org/10.2174/187152607782110022
DOI https://dx.doi.org/10.2174/187152607782110022 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
Call for Papers in Thematic Issues
New Frontiers in Infectious Disease Research: Small-Molecule Probes and Biomarker Identification
The biological relevance of small-molecule chemical probes targeting a disease model is crucial in the early stages of drug discovery. The integration of omics technologies such as genomics, proteomics, metabolomics, immunomic, and cellular levels has greatly enhanced the ability to identify novel biomarkers and understand the complex interactions between pathogens ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cytochrome P450s: Mechanisms and Biological Implications in Drug Metabolism and its Interaction with Oxidative Stress
Current Drug Metabolism Formulation of Nanosuspensions as a New Approach for the Delivery of Poorly Soluble Drugs
Current Nanoscience Antiretroviral Treatment of HIV Infection Does Not Influence HIVSpecific Immunity but Has an Impact on Non-Specific Immune Activation
Current HIV Research Di- and Sesquiterpenoids from Cystoseira Genus: Structure, Intra-molecular Transformations and Biological Activity
Mini-Reviews in Medicinal Chemistry Intracellular Activity of Poly (DL-Lactide-co-Glycolide) Nanoparticles Encapsulated with Prothionamide, Pyrazinamide, Levofloxacin, Linezolid, or Ethambutol on Multidrug-Resistant <i>Mycobacterium tuberculosis</i>
Current Drug Delivery Anti-Interleukin-6 Receptor Antibody Therapy in Rheumatic Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Patent Selections
Recent Patents on Biotechnology Human Tuberculosis I. Epidemiology, Diagnosis and Pathogenetic Mechanisms
Current Medicinal Chemistry Heat Shock Proteins (HSPs) Based Anti-Cancer Vaccines
Current Molecular Medicine Update of QSAR & Docking Studies of the GSK-3 Inhibitors
Current Bioinformatics Comparative Study on Synthesis and Biological, Pharmaceutical Applications of Aromatic Substituted Chalcones
Mini-Reviews in Organic Chemistry Pleural Fluid Analysis for Evaluating Pleural Effusions
Current Respiratory Medicine Reviews Therapeutic Drugs that Behave as Mechanism-Based Inhibitors of Cytochrome P450 3A4
Current Drug Metabolism Synthesis and SAR Study of Simple Aryl Oximes and Nitrofuranyl Derivatives with Potent Activity Against Mycobacterium tuberculosis
Letters in Drug Design & Discovery Recent Advances of 2-Quinolone-Based Derivatives as Anti-Tubercular Agents
Anti-Infective Agents Sodium Bromate/Sodium Hydrogen Sulfite: A New Catalyst for the Synthesis of Quinoxaline Derivatives
Letters in Organic Chemistry Preclinical Models of Multiple Sclerosis: Advantages and Limitations Towards Better Therapies
Current Medicinal Chemistry Meet Our Editorial Board Member
Infectious Disorders - Drug Targets Anti-Microbial
Current Bioactive Compounds Proteasome Inhibitors: Recent Advances and New Perspectives In Medicinal Chemistry
Current Topics in Medicinal Chemistry